UPDATE: The Ginkgold Ginkgo Biloba Class Action Settlement was granted final approval on January 25, 2021. Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page. Please note that claims will not be paid until after the claim deadline of February 24, 2021 passes.
The manufacturer of Nature’s Way supplements has agreed to pay around $3.4 million to resolve claims it misrepresented its Ginkgold products.
The settlement benefits individuals who purchased Ginkgold or Ginkgold Max in California between July 7, 2011, and Oct. 1, 2020, or between Jan. 1, 2016, and Oct. 1, 2020, if purchased anywhere else in the United States.
Plaintiffs in the Ginkgold class action lawsuit argued Nature’s Way manufacturer Schwabe North America Inc. misleadingly marketed its products as able to provide memory and concentration benefits.
Ginkgold supplements, sold as tablets, contain ginkgo biloba, a type of tree native to China. Although the plant’s leaves and seeds have been used in traditional Chinese medicine to help with brain function and blood circulation, the Ginkgold class action lawsuit argues no scientific studies have been done to support these uses.
“Numerous scientifically valid studies, performed by independent researchers and published in reputable medical journals, have been conducted on ginkgo biloba, and they have universally demonstrated that ginkgo biloba does not improve brain function, and is not effective in the treatment or improvement of memory problems or cognitive health,” the class action lawsuit contends.
Despite a lack of scientific support, Nature’s Way allegedly misrepresents its Ginkgold products in order to deceive consumers and encourage them to make purchases based on false promises.
The company also sells Ginkgold Eyes supplements, which the company claims support “the retina and macula health.”
Nature’s Way has not admitted any wrongdoing but has agreed to resolve the claims against it in a class action settlement. The company will pay nearly $3.4 million as part of the settlement in order to avoid the risks and costs of continuing litigation.
Under the terms of the settlement, Class Members can collect reimbursement of between $18 and $33 per product. Payments will provide reimbursement at a blended average between the cost of Ginkgold and Ginkgold Max products.
Class Members can collect $18 for Ginkgold Max 30 tabs, Ginkgold 50 tabs and Ginkgold 75 tabs, and $33 for Ginkgold 150 tabs, Ginkgold 100 tabs and Ginkgold Max 60 tabs. Exact payment amounts will vary depending on the number of purchases and types of products claimed by each Class Member.
In order to benefit from the class action settlement, Class Members must file a valid claim form by Feb. 24, 2021. Documentation of purchases such as receipts are required if Class Members seek reimbursement for more than three purchases. If Class Members do not have proof of purchase, they can only claim up to three purchases.
The deadline for exclusion and objection is Dec. 28, 2020. The final approval hearing for the Ginkgold class action settlement is scheduled for Jan. 25, 2021.
Individuals who purchased Ginkgold or Ginkgold Max in California between July 7, 2011 and Oct. 1, 2020 may make a claim. Also included in the settlement are those who purchased the products between Jan. 1, 2016 and Oct. 1, 2020 if purchased anywhere else in the United States.
Covered products include:
- Ginkgold 60 mg (50 tablets);
- Ginkgold 60 mg (75 tablets);
- Ginkgold 60 mg (100 tablets);
- Ginkgold 60 mg (150 tablets);
- Ginkgold Max 120 mg (30 tablets); and
- Ginkgold Max 120 mg (60 tablets).
Cash payments between $18 and $33 per product.
Payments will provide reimbursement at a blended average between the cost of Ginkgold and Ginkgold Max products – $18.00 for Ginkgold Max 30 tabs, Ginkgold 50 tabs and Ginkgold 75 tabs; and $33.00 for Ginkgold 150 tabs, Ginkgold 100 tabs and Ginkgold Max 60 tabs. Exact payment amounts will vary depending on the number of purchases and types of products claimed by each Class Member.
Proof of Purchase
Documentation of purchases such as receipts are required if Class Members seek reimbursement for more than three purchases.
NOTE: If you do not qualify for this settlement do NOT file a claim.
Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.
Claim Form Deadline
Kathleen Sonner, et al. v. Schwabe North America Inc., et al., Case No. 5:15-cv-01358, in the U.S. District Court for the Central District of California
c/o JND Legal Administration
P.O. Box 91231
Seattle, WA 98111
Timothy G. Blood
Leslie E. Hurst
Thomas J. O’Reardon II
Paula R. Brown
BLOOD HURST & O’REARDON LLP
Todd D. Carpenter
CARLSON LYNCH LLP
Kevin W. Alexander
Thomas R. Watson
GORDON REES SCULLY MANSUKHANI LLP
Jan M. Conlin
Katie Crosby Lehmann
CIRESI CONLIN LLP
Read About More Class Action Lawsuits & Class Action Settlements:
Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.